Inhaled and Nasal Biologics/DNA Forum 2023

Join us for a ground-breaking and insightful forum on inhaled and nasal biologics development: Two days of cutting-edge talks and networking opportunities with leaders in this complex area of inhaled biologics and inhaled vaccine development. Don't miss out - Tickets are limited and so register now!
2nd Annual Inhaled & Nasal Biologics/DNA Forum
28-29th September 2023 | Cambridge, UK
As drug discovery programs place greater emphasis on biologic drug substances for both local respiratory and systemic targets, the need to develop effective solutions for nasal and inhaled biologics delivery is becoming increasingly important for the industry. Respiratory administration of biologics and DNA modalities pose distinct obstacles. Developers must carefully balance various factors, including product performance, manufacturability, regulatory risk, and commercial considerations when designing a product.
This year's conference, centred around the theme of "Building Effective Products," features world-renowned industry leaders who will share the latest insights and case studies in the field of inhaled or nasal biologics and inhaled vaccine development with real-world case studies to stimulate discussion.
Join industry-leading experts for two
days of conference and networking. Grab your seat as a key stakeholder in this growing
industry community now.
Places are limited - please register now.
DOWNLOAD BROCHURE FOR LATEST AGENDA
Wednesday, September 27th 2023 - Networking and Optional Lab Tour
- Intertek Laboratory Tour (optional), Intertek Melbourn, Cambridgeshire, 2 pm
- Networking drinks reception, Hinxton Hall, 5.30 pm
Thursday, 28th September 2023 - Day 1 of Conference
- Keynote Speaker: Igor Gonda, Founder and CEO, Respidex LLC
Inhaled biologics: What can we learn from Pulmozyme success 30 years later?
Pulmozyme was the first and so far the only approved inhaled recombinant human protein. It was launched in record time of 4 years from cloning the molecule, despite no prior regulatory precedents. Many believed that this success heralded entry of many new inhaled biologics both for treatment of respiratory diseases as well as a non-invasive route of administration of macromolecules. The debacle of inhaled insulin brought the field to a screeching halt. This talk will discuss the lessons learned that include the key criteria for the choice of the target product profile for inhaled biologics and the tools needed to develop successfully such products.
- Session 1: Learnings from Real-World Case Studies
- Session 2: Choosing The Right Drug Delivery Device
- Panel Discussion
- Networking Drinks 5:30 pm
- Evening: Conference Dinner
Friday, 29th September 2023 - Day 2 of Conference
- Session 3: Designing An Appropriate Formulation
- Session 4: Regulatory-Driven Test Requirements
- Conference Close
Meet Our Speakers
![]() | Keynote Speaker: Igor Gonda, Founder and CEO, Respidex LLCIgor Gonda is the founder of Respidex LLC – a consulting firm assisting pharmaceutical companies in corporate strategy, including R&D program design, collaborations with patient advocacy groups, regulatory process, intellectual property management, financing and business development. He is a Principal Consultant for Scendea - a product development and regulatory consulting practice. He was previously in various executive roles (Chief Scientific Officer, CEO and President) at Aradigm Corporation – a US company developing inhalation therapies for the prevention and treatment of serious respiratory and systemic diseases.
|
![]() |
|
![]() | Ross Blezard Product Application Specialist Biopharma and Inhalation.The Role of Excipients in the Future of Pulmonary Drug Delivery
|
![]() | Mathieu Epardaud, PhD Senior scientist @ INRAe Co-founder and Scientific consultant @ LoValTech Challenges and Opportunities of a Mucosal Platform for Nasal Vaccination
|
![]() | Bruce Hamilton, PhD Drug Development Team Leader, Early Phase Development Solutions Labcorp Early Development Laboratories Limited Non-clinical development of inhaled biopharmaceuticals and newer classes of compounds compared to inhaled NCEs
|
![]() | David Coleman Drug Development Leader, Inhaled Drug Development, Labcorp Early Development Laboratories Limited Non-clinical development of inhaled biopharmaceuticals and newer classes of compounds compared to inhaled NCEs
|
![]() | Professor Cees van Rijn Senior Researcher, University of Amsterdam and Director IPR at Medspray B.V. Aerosolization of Biologics by Different Soft Mist and Nebulizer Technologies
|
![]() | Professor Ben Forbes Professor of Pharmaceutics King's College London Development of mRNA Formulations for Inhaled Drug Delivery
|
![]() | Jacob Harker Director BnL Pharma Solutions Inhaled Oxytocin, Bringing safer Childbirth to Women in Need
|
![]() | Pete Lambert Director, Program Management Monash Institute of Pharmaceutical Sciences Inhaled Oxytocin, Bringing safer Childbirth to Women in Need
|
![]() | Kaoutar Kristou Area Sales Manager Northern EU, Aptar Pharma Rx Aptar Pharma Rx Nasal Device Optimization: Balancing Formulation and Patient Needs
|
![]() | Ashleigh Wake Business Development Director Intertek DNA Medicine Testing for Inhaled and Nasal Oligonucleotide and mRNA Products
|
REGISTRATION
The registration fee per attendee is shown below. This includes the conference registration, accommodation at Hinxton Hall if required, the conference dinner and networking drinks.
Rate | Incl. 2 nights' accommodation | Incl. 1 night accommodation | No accommodation required |
Standard Rate (from 1 June 2023) | £449 | £399 | £349 |
LOCATION
Set within a one-hundred-acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.
Hinxton Hall is 25 minutes from the centre of Cambridge, and a mere 60 minutes from London and accessible from Heathrow, Luton and Gatwick airports and is only 20 minutes from London Stansted Airport. The hall is easily accessible from the M11. For GPS please use: CB10 1SA.
The Intertek team will book accommodation on your behalf if you indicate that you require a room during registration.
QUESTIONS? Please contact us:
T: UK +44 (0)1763 261 648 | E: inhaled.biologics@intertek.com
With drug discovery programmes increasingly focused on biological drug substances for both respiratory and systemic targets, the need to develop effective solutions for nasal and inhaled delivery is becoming increasingly vital for the industry. Biologic and DNA based modalities such as oligonucleotides, proteins, antibodies and a range of other complex forms present unique challenges for developing an effective inhaled and nasal delivery.
With a focus on networking and learning, Intertek was delighted to host the first forum on all aspects of the development of biologic drugs for respiratory delivery which took place at Madingley Hall, Cambridge from 28-30 September 2022.
We thank all of our industry leading experts who joined us for discussions on key principles, challenges, regulatory expectations, best practice and technologies involved in building effective inhaled and nasal DNA or biologic product. The agenda included these talks:
PLENARY: Complex large molecules delivered to the nose and lungs by devices as a combination product. Whatever could be simpler than that!
Eddie J French PhD, TEKH Consulting Limited
Inhaled Biologics – Time to Deliver!
Professor Ben Forbes, Professor of Pharmaceutics, King's College London
Smart nebulizers, the future role of technology in respiratory care
Ulf Krüger, CEO, Pulmotree Medical GmbH
Inhaled IFN-β (SNG001) for the treatment of COVID-19 and other severe viral lung infections
Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd
Inhaled Biologics: What Molecules? What Markets?
Philippe Rogueda – Co-founder and Chief Business Officer, Merxin Ltd.
Fundamentals of OINDP Testing
Mark Parry, Technical Director, Intertek
Fundamentals of DNA Medicines Testing for Inhaled and Nasal Oligonucleotide and mRNA Products
Ashleigh Wake, Intertek Pharmaceutical Services
Intertek Melbourn
GMP Pharmaceutical Analysis and Formulation Expertise
Intertek Melbourn
Saxon Way, Melbourn
Herts, SG8 6DN
UK
Recent News:
Laboratory Expansion for Specialist OINDP Development for Biologics